Advertisement
UK markets close in 5 hours 9 minutes

  • FTSE 100

    8,395.07
    -21.38 (-0.25%)
     

  • FTSE 250

    20,767.75
    -15.62 (-0.08%)
     

  • AIM

    806.43
    -0.66 (-0.08%)
     

  • GBP/EUR

    1.1740
    +0.0034 (+0.29%)
     

  • GBP/USD

    1.2731
    +0.0020 (+0.15%)
     

  • Bitcoin GBP

    55,013.61
    -939.30 (-1.68%)
     

  • CMC Crypto 200

    1,516.21
    -10.21 (-0.67%)
     

  • S&P 500

    5,321.41
    +13.28 (+0.25%)
     

  • DOW

    39,872.99
    +66.22 (+0.17%)
     

  • CRUDE OIL

    78.02
    -0.64 (-0.81%)
     

  • GOLD FUTURES

    2,421.30
    -4.60 (-0.19%)
     

  • NIKKEI 225

    38,617.10
    -329.83 (-0.85%)
     

  • HANG SENG

    19,195.60
    -25.02 (-0.13%)
     

  • DAX

    18,685.21
    -41.55 (-0.22%)
     

  • CAC 40

    8,103.37
    -38.09 (-0.47%)
     
Property:

The UK’s most expensive coastal town

Average home in this seaside town costs over £1m

Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks Equity Research
·2-min read

Neurocrine Biosciences (NBIX) reported $515.3 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 22.6%. EPS of $0.42 for the same period compares to -$0.79 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $512.21 million, representing a surprise of +0.60%. The company delivered an EPS surprise of -59.62%, with the consensus EPS estimate being $1.04.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

ADVERTISEMENT

Here is how Neurocrine performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Collaboration revenue: $6.30 million versus $7.68 million estimated by 10 analysts on average. Compared to the year-ago quarter, this number represents a +23.5% change.

  • Revenues- Product sales, net: $509 million compared to the $505.50 million average estimate based on nine analysts. The reported number represents a change of +22.6% year over year.

  • INGREZZA product sales, net: $506 million compared to the $505 million average estimate based on eight analysts. The reported number represents a change of +23.3% year over year.

View all Key Company Metrics for Neurocrine here>>>

Shares of Neurocrine have returned -0.2% over the past month versus the Zacks S&P 500 composite's -4.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Neurocrine Biosciences, Inc. (NBIX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research